- Home
- PTN vs ATHA Comparison
PTN vs ATHA Comparison
Compare PTN & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTN
- ATHA
- Stock Information
- Founded
- PTN 1986
- ATHA 2011
- Country
- PTN United States
- ATHA United States
- Employees
- PTN N/A
- ATHA N/A
- Industry
- PTN Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PTN Health Care
- ATHA Health Care
- Exchange
- PTN Nasdaq
- ATHA Nasdaq
- Market Cap
- PTN 25.4M
- ATHA 22.3M
- IPO Year
- PTN 1993
- ATHA 2020
- Fundamental
- Price
- PTN $0.78
- ATHA $0.54
- Analyst Decision
- PTN Strong Buy
- ATHA Buy
- Analyst Count
- PTN 1
- ATHA 4
- Target Price
- PTN $17.00
- ATHA $11.25
- AVG Volume (30 Days)
- PTN 365.1K
- ATHA 325.4K
- Earning Date
- PTN 02-13-2025
- ATHA 11-07-2024
- Dividend Yield
- PTN N/A
- ATHA N/A
- EPS Growth
- PTN N/A
- ATHA N/A
- EPS
- PTN N/A
- ATHA N/A
- Revenue
- PTN $2,384,113.00
- ATHA N/A
- Revenue This Year
- PTN N/A
- ATHA N/A
- Revenue Next Year
- PTN N/A
- ATHA N/A
- P/E Ratio
- PTN N/A
- ATHA N/A
- Revenue Growth
- PTN N/A
- ATHA N/A
- 52 Week Low
- PTN $0.68
- ATHA $0.41
- 52 Week High
- PTN $5.65
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- PTN 34.59
- ATHA 36.91
- Support Level
- PTN $0.82
- ATHA $0.56
- Resistance Level
- PTN $0.99
- ATHA $0.61
- Average True Range (ATR)
- PTN 0.11
- ATHA 0.04
- MACD
- PTN -0.02
- ATHA -0.01
- Stochastic Oscillator
- PTN 16.64
- ATHA 8.45
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.